Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274661 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
A Phase 2 study of Solid Tumor, Adult, sponsored by Baptist Health South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT03274661 is a Phase 2 study of Solid Tumor, Adult that has completed, run by Baptist Health South Florida. The registered enrollment target is 52 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03274661, a Phase 2 study of Solid Tumor, Adult, has completed, sponsored by Baptist Health South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial in which patients with metastatic solid tumors experiencing progression after first line standard chemotherapy or for which there is no standard chemotherapy, and for which pembrolizumab does not have an FDA or compendia listing approved indication, will receive pembrolizumab intravenously at a dose of 200 mg every 3 weeks.
Conditions Studied
Interventions
- DRUG Pembrolizumab 200 mg Q3W
Study Locations (1)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2022-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03274661
The ClinicalTrials.gov registry entry for NCT03274661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (73% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab 200 mg Q3W is the first listed.
NCT03274661 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03274661 about?
NCT03274661 is a clinical study titled "Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors". Phase II trial in which patients with metastatic solid tumors experiencing progression after first line standard chemotherapy or for which there is no standard chemotherapy, and for which pembrolizumab does not have an FDA or compendia listing approved indication, will receive pembrolizumab intraven...
What is the current status of trial NCT03274661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2017-11-03. Estimated completion is 2022-03-19.
What conditions does trial NCT03274661 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT03274661?
The interventions under investigation include: Pembrolizumab 200 mg Q3W (DRUG).
Who is sponsoring clinical trial NCT03274661?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03274661 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
-
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
RECRUITING
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.